论文部分内容阅读
目的 探讨癌基因bcl 2 ,c myc和 p5 3在大肠腺瘤与大肠癌中的表达情况及与临床病理特征的关系。 方法 采用免疫组化ABC法 ,检测 63例大肠癌和 40例大肠腺瘤的bcl 2 ,c myc和 p5 3表达。 结果 bcl 2 ,c myc和 p5 3在大肠腺瘤中的表达分别为 72 .7% ( 2 4/3 3 )、62 .2 % ( 2 3 /3 7)和 45 .0 % ( 18/4 0 ) ,而在大肠癌中的表达则依次为 3 4 .0 % ( 16/4 7)、82 .1% ( 3 2 /3 9)和 84.1% ( 5 3 /63 )。三个癌基因在大肠腺瘤和大肠癌中的表达均有显著的统计学意义 (P <0 .0 1) ,但三个癌基因的表达与临床病理特征无显著的相关性。结论 bcl 2基因的异常激活在肿瘤的发展和演变出现较早 ,而c myc和p5 3的表达则较迟 ,且两者起协同作用。
Objective To investigate the expression of oncogene bcl 2, c myc and p 5 3 in colorectal adenoma and colorectal carcinoma and its relationship with clinicopathological features. Methods Immunohistochemical ABC method was used to detect the expressions of bcl 2, c myc and p 5 3 in 63 cases of colorectal carcinoma and 40 cases of colorectal adenoma. Results The expressions of bcl-2, c-myc and p-5 in colorectal adenoma were 72.7% (2/3/3), 62.2% (23/37) and 45.0% (18/4 0), while in colorectal cancer, 34.0% (16/47), 82.1% (32/39) and 84.1% (53/63), respectively. The expression of three oncogenes in colorectal adenoma and colorectal cancer both had significant statistical significance (P <0.01), but the expression of three oncogenes had no significant correlation with clinicopathological features. Conclusion Abnormal activation of bcl 2 gene appeared earlier in tumor development and later in c-myc and p5 3 expression, and both of them play a synergistic effect.